Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution.
about
Regional therapies for in-transit diseasePlasma cytokine analysis in patients with advanced extremity melanoma undergoing isolated limb infusion.Chemotherapeutic agents subvert tumor immunity by generating agonists of platelet-activating factor.Current treatment of locoregional recurrence of melanoma.Isolated limb infusion: Efficacy, toxicity and an evolution in the management of in-transit melanoma.A multicenter phase I dose escalation trial to evaluate safety and tolerability of intra-arterial temozolomide for patients with advanced extremity melanoma using normothermic isolated limb infusion.Isolated limb perfusion with hyperthermia and chemotherapy: predictive factors for regional toxicity.Resection of residual disease after isolated limb infusion (ILI) is equivalent to a complete response after ILI-alone in advanced extremity melanoma.Isolated limb infusion in a series of over 100 infusions: a single-center experience.Burden of disease predicts response to isolated limb infusion with melphalan and actinomycin D in melanoma.The Role of Regional Therapies for in-Transit Melanoma in the Era of Improved Systemic Options.A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanomaQuality of life after isolated limb infusion for in-transit melanoma of the extremity.Predicting disease progression after regional therapy for in-transit melanoma.A multi-institution experience comparing the clinical and physiologic differences between upper extremity and lower extremity melphalan-based isolated limb infusion.Immunotherapy following regional chemotherapy treatment of advanced extremity melanomaMinimally invasive intra-arterial regional therapy for metastatic melanoma: isolated limb infusion and percutaneous hepatic perfusion.Melphalan: a promising agent in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.Positron emission tomography in the follow-up of cutaneous malignant melanoma patients: a systematic reviewIsolated limb infusion with melphalan and actinomycin D for melanoma: a systematic review.Isolated limb infusion as a model to test new agents to treat metastatic melanoma.Electrochemotherapy for the management of melanoma skin metastasis: a review of the literature and possible combinations with immunotherapy.Regional therapy in metastatic melanoma: an update on minimally invasive intraarterial isolated limb infusion and percutaneous hepatic perfusion.Clinical Response and Regional Toxicity Following Isolated Limb Infusion Compared with Isolated Limb Perfusion for In-Transit Melanoma.Isolated Limb Perfusion for Melanoma is Safe and Effective in Elderly Patients.Factors associated with response, survival, and limb salvage in patients undergoing isolated limb infusion.Patterns of recurrence following complete response to regional chemotherapy for in-transit melanoma.Efficacy of repeat sentinel lymph node biopsy in patients who develop recurrent melanoma.
P2860
Q28087553-CCD51239-891F-489E-87B5-26CBE8805A31Q34464096-2003BF32-6CD8-4D49-9689-5EB08568265BQ34613089-51FA2B21-4037-4947-88B9-FDA5ADC081BCQ34888462-756DB755-7303-4594-9EA7-A84A9529FB2DQ35189712-0A63D6B2-8BEA-486B-951E-DB64B6BFF878Q35731493-7BFC0B2F-2664-40A2-8BEA-0042A149711BQ35813429-A21551E1-D85E-4A2C-85D8-EC8B6A858963Q35857551-FE3DDCED-EBB8-445B-9C8D-B16975DDB2D7Q35857556-D25F64BB-B2E6-4D95-ACB2-297D48C86C0DQ35861663-928F82CB-AC93-40B3-9CD4-0342D538938AQ36102807-2F6CC557-A9DC-4BEE-8ED5-99AAE39F9BEDQ36201336-168BE923-05AF-46A3-8BB7-790F463C988BQ37509676-36D3000D-7D12-4CB9-9AC5-846757041955Q37509683-C0AB12AE-12F0-4C8D-BCBF-30D61BD482AFQ37509704-1EB5E7C7-022C-4CC8-971E-0782EC4E5C73Q37509709-64727759-2FEF-410B-BCCD-822747A35725Q37943015-625E42D2-C070-4927-9D37-E9A6651DE521Q38166245-07C1BEB6-5DA0-4968-A6B3-6D1222338D56Q38174901-DEACD3A0-E2CB-49CB-816B-59F97B313E09Q38187594-2BC202A8-39B0-42EE-B2DC-3E70B72458D0Q38187595-B6B27579-8B7E-49F1-93F2-7A5AF71894C2Q38200527-BB5E9483-DA15-4324-B446-9676736506DDQ38245172-A2ED16B2-F01A-469C-9316-3E1AA669F5CDQ38754840-6D131642-0840-49E6-A8E6-D4E391E7FF97Q38966445-20226E1F-0219-40CC-9B81-08A24D72F172Q43654354-9F295120-E0AD-4128-BC26-80B910EF6778Q44752180-6C9DAF72-12EC-40D1-8630-5AB56E91BAC8Q55392419-EC659FF1-A3C7-4A89-B8EC-DA1FA56AA8BA
P2860
Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Current trends in regional the ...... 2010 at a single institution.
@ast
Current trends in regional the ...... 2010 at a single institution.
@en
type
label
Current trends in regional the ...... 2010 at a single institution.
@ast
Current trends in regional the ...... 2010 at a single institution.
@en
prefLabel
Current trends in regional the ...... 2010 at a single institution.
@ast
Current trends in regional the ...... 2010 at a single institution.
@en
P2093
P2860
P50
P1476
Current trends in regional the ...... 2010 at a single institution.
@en
P2093
Bercedis Peterson
Christina K Augustine
Douglas S Tyler
Hilliard Seigler
James C Padussis
Ryan Turley
Scott K Pruitt
P2860
P304
P356
10.1016/J.JAMCOLLSURG.2011.03.013
P577
2011-04-13T00:00:00Z